Details

Autor(en) / Beteiligte

• KOH, Won-Jung
• SEUNG HEON LEE
• SANG BONG CHOI
• YON JU RYU
• KYUNG CHAN KIM
• SOOJUNG UM
• YONG SOO KWON
• YEE HYUNG KIM
• CHOI, Won-Il
• KYEONGMAN JEON
• YONG IL HWANG
• SE JOONG KIM
• YOUNG AE KANG
• YOUNG SEOK LEE
• EUN YOUNG HEO
• JUHEE LEE
• YEO WOON KI
• TAE SUN SHIM
• YIM, Jae-Joon
• LEE, Chang-Hoon
• JAE CHOL CHOI
• JAE HO LEE
• SEUNG HUN JANG
• KWANG HA YOO
• KI HWAN JUNG
• KI UK KIM

Titel

Comparison of Levofloxacin versus Moxifloxacin for Multidrug-Resistant Tuberculosis

Ist Teil von

• American journal of respiratory and critical care medicine, 2013-10, Vol.188 (7), p.858-864

Ort / Verlag

New York, NY: American Thoracic Society

Erscheinungsjahr

2013

Quelle

MEDLINE

Beschreibungen/Notizen

• Levofloxacin (LFX) and moxifloxacin (MXF) are the two most frequently recommended fluoroquinolones for treatment of patients with multidrug-resistant tuberculosis (MDR-TB). However, studies comparing the effectiveness of LFX and MXF among patients with MDR-TB are lacking. To compare the effectiveness of LFX and MXF in terms of culture conversion after 3 months of treatment for MDR-TB. In this prospective multicenter randomized open label trial, we randomly assigned 182 patients with MDR-TB (sensitive to LFX and MXF) to receive either LFX (750 mg/day; 90 patients) or MXF (400 mg/day; 92 patients) with a background drug regimen. The primary outcome was the proportion of patients who achieved sputum culture conversion at 3 months of treatment. Secondary outcomes were time to culture conversion and time to smear conversion, with data censored at 3 months, and the proportions of adverse drug reactions. At 3 months of treatment, 68 (88.3%) of the 77 patients in the LFX group and 67 (90.5%) of the 74 in the MXF group showed conversion to negative sputum cultures (odds ratio for LFX compared with MXF, 0.78; 95% confidence interval, 0.27-2.20). Adverse drug reactions were reported in six patients (7.7%) in the LFX group and four (5.2%) in the MXF group (P = 0.75). The choice of LFX or MXF for treatment of patients with MDR-TB may not affect sputum culture conversion at 3 months of treatment. Clinical trial registered with www.clinicaltrials.gov (NCT 01055145).